Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 85Years
All Genders
NCT07098598

Pancreatic Cancer Diagnosis With FAPI-PET Imaging

Led by Turku University Hospital · Updated on 2025-08-01

100

Participants Needed

1

Research Sites

103 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Staging pancreatic cancer (PC) presents a clinical challenge. Triphasic whole body CT is the primary imaging method in diagnosing, staging and during follow up. Conventional PET/CT with 18F-labelled fluorodeoxyglucose (18F-FDG) has its limitations and therefore has a secondary role in imaging pancreatic cancer patients. These conventional imaging methods are good in detecting primary tumors and distant metastasis but poor in detecting local lymph node metastasis. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targets FAP, a protein overexpressed in cancer-associated fibroblasts. It presents a potential new PET imagining tool. The objective of this prospective diagnostic study is to evaluate the diagnostic efficacy of 18F-FAPI-74 PET/CT in patients with PC. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with PC in primary staging and when suspected recurrence. 100 patients with PC are enrolled on whom PET/CT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.

CONDITIONS

Official Title

Pancreatic Cancer Diagnosis With FAPI-PET Imaging

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Suspected primary or recurrent pancreatic cancer
  • Male or female aged 18 to 85 years
  • WHO performance score 0 to 2
  • Able and willing to provide written informed consent and comply with study requirements
Not Eligible

You will not qualify if you...

  • Vulnerable subjects such as disabled, children, pregnant or breastfeeding women, and prisoners
  • Unable to understand the purpose of the study
  • Medical conditions preventing whole-body PET/CT imaging

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Turku PET Centre, Turku University Hospital

Turku, Finland

Actively Recruiting

Loading map...

Research Team

S

Saila Kauhanen, docent

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Pancreatic Cancer Diagnosis With FAPI-PET Imaging | DecenTrialz